ESMO / ECC Conference Coverage
Featured Articles
(BioPharma Dive) Oct 19, 2018 - Clovis Oncology, trailing PARP inhibitor rivals AstraZeneca and Tesaro, aims to jump ahead in a new market for the targeted therapies, announcing Friday positive early data for its drug Rubraca in metastatic castration-resistant prostate cancer.
Read Article
(Novartis) Oct 19, 2018 - Novartis today announced presentation of a new analysis of Lutathera® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden. The data show that Lutathera...
Read Article
Latest Articles
October 19, 2018
October 19, 2018
October 19, 2018
October 19, 2018
October 19, 2018
October 19, 2018
October 19, 2018
October 19, 2018
View More
News Commentary
There is no ESMO / ECC Conference Coverage commentary.

OBR Green
There are no ESMO / ECC Conference Coverage OBR Green articles.
Featured Videos
There are no videos.
OBR Blog
There are no ESMO / ECC Conference Coverage blog entries.